+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cryptococcosis Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 4896168
  • Report
  • June 2020
  • Region: Global
  • 113 pages
  • Mordor Intelligence

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Glenmark Pharmaceuticals
  • Novartis AG
  • Pfizer Inc.
Cryptococcosis is a fungal infection which is caused by Cryptococcus neoformans and Cryptococcus gattii which primarily affects the central nervous system and the lungs. People with diseases such as AIDS, hodgkin lymphoma, other lymphomas, sarcoidosis, and solid organ transplantation with weakened immune systems are generally more susceptible to this type of infection.

Cryptococcosis is usually acquired by inhalation of dust containing yeast cells which typically affects the lungs. Cryptococcosis symptoms include fever, malaise, cough, hemoptysis (bloody or blood-tinged sputum), headache, vision changes (blurry or double vision, photophobia) etc. Cryptococcosis diagnosis is clinical and microscopic, which is confirmed by culture or fixed-tissue staining.

According to the United Nations Program on HIV/AIDS and the World Health Organization, globally approximately one million cases of cryptococcosis are reported each year resulting in 625,000 deaths approximately. According to the Centers for Disease Control and Prevention and WHO, it is estimated that globally every year 220,000 cases of cryptococcal meningitis occur among people with HIV/AIDS, resulting in nearly 181,000 deaths. Therefore with the growing prevalence of cryptococcosis and availability of advance treatment are the key factors that drives the growth of cryptococcosis diseases market. However, adverse effects associated with the use of medication is likely to restrain the market growth in the forecast period.

Key Market Trends

Flucytosine Segment is Expected to Hold a Significant Market Share

Flucytosine is a small, water-soluble molecule which is a nucleoside analog antifungal drug that acts by disrupting pyrimidine metabolism in the fungal cell nucleus. Flucytosine is generally given as first-line treatment in combination with other antifungal medications. Flucytosine was major revenue holding segment because it is given as first-line treatment in combination with other antifungal medications.

According to the United Nations Program on HIV/AIDS and the World Health Organization, globally approximately one million cases of cryptococcosis are reported each year resulting in 625,000 deaths approximately. The increasing prevalence of cryptococcosis and increasing new and advanced treatment opportunities are the key factors for the growth of the cryptococcosis market.

North America is Expected to Dominate the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major share globally in cryptococcosis market due to the rising prevalence of cryptococcosis, the rise in technological advancements, and higher cost of medication in this region.

As per the study article published by National Institute of Health in 2019, in the United States prevalence of cryptococcosis is estimated to be about 0.4-1.3 cases per 100,000 population and 2-7 cases per 100,000 in people affected with AIDS with a case fatality ratio of about 12%. Therefore, North America holds a major market share due to the rising prevalence of cryptococcosis in the endemic areas that are fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Cryptococcosis Therapeutics Market is moderately consolidated and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some companies are adopting numerous strategies including acquisitions and collaborations to sustain market competition.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Glenmark Pharmaceuticals
  • Novartis AG
  • Pfizer Inc.
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Prevalence of Fatal Fungal Disease
4.2.2 Favourable Reimbursement Policies
4.2.3 New and Advanced Treatment Opportunities
4.3 Market Restraints
4.3.1 Adverse Effects of the Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Treatment
5.1.1 Amphotericin B
5.1.2 Flucytosine
5.1.3 Fluconazole
5.1.4 Others
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle-East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Astellas Pharma Inc
6.1.2 Bristol-Myers Squibb Company
6.1.3 Glenmark Pharmaceuticals
6.1.4 Janssen Biotech Inc. (Johnson & Johnson)
6.1.5 Novartis AG
6.1.6 Pfizer Inc.
6.1.7 Sigmapharm Laboratories LLC
6.1.8 Valeant Pharmaceuticals Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals
  • Janssen Biotech Inc. (Johnson & Johnson)
  • Novartis AG
  • Pfizer Inc.
  • Sigmapharm Laboratories LLC
  • Valeant Pharmaceuticals Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll